Maxcyte Share Discussion Threads

[adamb1978] 30/1/2024 18:34

Certainly could be. COuld understand people holding back signing a long-term license agreement til it was proven.

Hopefully its not the new guy at the top accepting less attractive commercial terms

[mysteronz] 30/1/2024 16:38

These SPL signings are really starting to grow now.

Maybe a sign of increased confidence in bio investment or the MXCT platform, either way future money in the bank/sign on fee :)

[adamb1978] 08/1/2024 21:54

Thanks. Nice beat resulting from hte Vertex milestone payment. Hopefully they order piles more of the consumables for the next stage of that therapy and that with one test case through the FDA, it makes other customers more risk tolerant about submitting approval requests of their own

[davep4] 08/1/2024 21:23

Preliminary Unaudited Fourth Quarter and Full Year 2023 Results

Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.

Core revenue is expected to be between $7.0 million and $7.2 million, compared to $10.6 million in the fourth quarter of 2022.
Strategic Platform License (SPL) Program-related revenue is expected to be approximately $8.5 million, compared to $1.9 million in the fourth quarter of 2022.
Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.

Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.
SPL Program-related revenue is expected to be approximately $11.4 million, compared to $4.6 million for fiscal year 2022.
Total cash, cash equivalents, and investments as of December 31, 2023 is expected to be approximately $210 million.

[davep4] 12/12/2023 13:20

Maybe the current share price performance resulted in DD being pushed into retirement? Whatever agreement has been reached it appears on the surface to be amicable.

Nevertheless, I am pleased that I will not have read about his continuous Exercise of Options and subsequent sale, (which in my opinion damaged the SP), furthermore, such Exercise of Options indicates to me that he knew he was going.

[adamb1978] 12/12/2023 06:25

Well I guess it was perhaps a $5m fee or so on FDA approval. THey had suggested before that they might be able to make the $6m without this, but the wording around it made it sound like a stretch. Now its "at least" $10m

DD retirement is a surprise, or at least the very near-term date. Wonder whether he's ill or something.

[junior21] 12/12/2023 05:36

Last SPL guidance was $6m so modest but welcome increase

[davep4] 11/12/2023 23:55

Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte

Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024

MaxCyte is reiterating 2023 expected core business revenue of $28-30 million, and the Company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million

[davep4] 11/12/2023 23:47

Duplicate post.

[davep4] 11/12/2023 23:47

Doug Doerfler, will retire as President and Chief Executive Officer, effective January 1, 2024.

…. the company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million.

[adamb1978] 11/12/2023 11:30

THeir milestone revenue target for the year, which was $6m from memory, I believe could have all be met, or close to being met, just from this one payment.

Hence expecting a RNS

[junior21] 11/12/2023 10:32

Adam, I read that CRISPR are receiving a $200m milestone payment following FDA approval. Can't very this but if true you would have thought Maxcyte's would be a decent amount.

[pob69] 11/12/2023 08:51

Also curious to see that this research provider appears to no longer cover MXCT. Their last note was 9/22 entitled "Vertex Pharmaceuticals secures exa-cel SPL". They are not the house broker though.



This note offers the most commentary on exa-cel

[adamb1978] 11/12/2023 08:19

Thanks Junior. Was expecting an RNS from MXCT this morning. The fee for them generated from the vertex approval is probably close to being a 'material' event relative to mkt expectations for revenue. Add in the future royalties, I think its certainly RNS-able

[junior21] 09/12/2023 22:46

Most of my info is gleaned from Twitter/ X so bear that in mind!

[junior21] 09/12/2023 22:45

The treatment is going to cost $2.2m per patient and maxcyte have a royalty of 3%, so $66k per patient in US money.

[adamb1978] 09/12/2023 20:17

Thanks Junior. That £50k is an interesting data-point. Can I ask where you saw that?

[junior21] 09/12/2023 15:44

Looking at the numbers for every administering of casgevy maxcyte will receive about £50,000. One forecast expects around 1,000 cases per year by 2032,but will be interesting to see how quickly it ramps up

[adamb1978] 08/12/2023 18:32

Very nice. Share price down 4% in NY!!

[lancasterbomber] 08/12/2023 17:36

Surprised share price went down not up

[junior21] 08/12/2023 16:47

Thanks pob. It was widely expected but I'm still relieved to see it has been approved.

Is the next key date in March?

[pob69] 08/12/2023 16:28

Confirmation

U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease

[junior21] 05/12/2023 16:02

I've no idea Adam, though as long as it's positive news I won't mind waiting!

[adamb1978] 04/12/2023 21:01

Thanks Junior21. Was wondering whether the FDA wait the full timetable or can come out with the news before then

Any idea whether it's before markets open in the US on Fri or afternoon or....?